Navigation Links
Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay

SAN DIEGO, Feb. 21 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) has submitted to the U.S. Food and Drug Administration (FDA) a supplemental regulatory application for the additional use of the PROCLEIX(R) ULTRIO(R) assay to screen donated blood for the hepatitis B virus (HBV), the Company announced today. The FDA approved the assay to screen donated blood for HIV-1 and the hepatitis C virus (HCV) in late 2006.

The Company is seeking approval to use the assay to screen for HBV on both its semi-automated instrument platform and on the fully automated, high-throughput TIGRIS(R) system.

"Demonstrating that our PROCLEIX ULTRIO assay is able to identify HBV-infected blood donations that serological tests miss and submitting this supplemental Biologics License Application (BLA) to the FDA are major milestones for our blood screening business, and may further safeguard the U.S. donated blood supply," said Hank Nordhoff, Gen-Probe's chairman and chief executive officer.

Gen-Probe's blood screening products are marketed worldwide by Chiron, a business unit of Novartis Vaccines and Diagnostics, Inc.


In October of 2006, the FDA approved the PROCLEIX ULTRIO assay to screen donated blood, plasma, organs and tissue for HIV-1 and HCV on Gen-Probe's semi-automated instrument system. In May of 2007, the FDA granted a similar approval to use the assay on the TIGRIS system.

However, the PROCLEIX ULTRIO assay was not approved to screen donated blood for HBV, as the initial pivotal study for the assay was not designed to, and did not, demonstrate HBV yield. Yield is defined as HBV-infected blood donations that were intercepted by the PROCLEIX ULTRIO assay, but that were initially negative based on serology tests for HBV surface antigen and core antibodies. Based on discussions with the FDA, Gen-Probe and Chiron agreed to conduct a post-marketing study of the PROCLEIX ULTRIO assay to demonstrate the HBV yield required for a donor-screening claim.

Gen-Probe began this post-marketing study in early 2007. To date, approximately 500,000 blood donations have been screened in the study, and two HBV yield cases have been identified. Data on these two yield cases comprise the foundation of the Company's supplemental BLA.

HBV is the most common serious liver infection in the world and is transmitted through contact with blood and body fluids. HBV infection can lead to liver failure, cirrhosis or cancer. According to the World Health Organization, more than 350 million people worldwide are chronically infected with HBV. More than one million people die annually as a result of HBV infections.


PROCLEIX and ULTRIO are trademarks of Novartis Vaccines and Diagnostics, Inc. TIGRIS is a trademark of Gen-Probe.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to

Caution Regarding Forward-Looking Statements

Any statements in this press release about Gen-Probe's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements concerning new products, potential regulatory approvals, customer adoption and potential milestone payments are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to: (i) the risk that new products, including the PROCLEIX ULTRIO assay, will not be cleared for marketing in the timeframes we expect, if at all, (ii) the risk that we may not earn or receive milestone payments from our collaborators, (iii) the possibility that the market for the sale of our new products, such as our PROCLEIX ULTRIO assay and PROCLEIX TIGRIS system, may not develop as expected, (iv) we may not be able to compete effectively, (v) we may not be able to maintain our current corporate collaborations and enter into new corporate collaborations or customer contracts, and (vi) we are dependent on Novartis and other third parties for the distribution of some of our products. The foregoing describes some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.


Michael Watts

Senior director, investor relations and

corporate communications


SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
2. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
3. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
8. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
9. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
10. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
11. EpiCept Provides Update on Clinical and Regulatory Progress with Ceplene(TM) and EpiCept(TM) NP-1 Cream
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  Ardelyx, Inc. ... focused on gastrointestinal and cardio-renal diseases, today announced ... candidate, tenapanor, will be presented at the 2015 ... findings will include measures of sustained response in ... blind, placebo-controlled, randomized Phase 2 trial. The meeting ...
(Date:10/8/2015)...  Trovagene, Inc., (NASDAQ:   TROV) a developer ... of results from a field experience analysis featuring ... (PCM) platform to accurately identify mutational status, ... appropriate therapy for patients. Mark Erlander , ... the results today in an oral presentation titled ...
(Date:10/8/2015)... Oct. 8, 2015  Following months of investigation, Ross ... the nation alleging that the anticoagulant Xarelto,s recommended dosage doesn,t ... Philadelphia on behalf of a ... stroke because the drug didn,t work as the manufacturer suggested. ... other suits shortly on behalf of clients from across the ...
Breaking Medicine Technology:
... /PRNewswire/ --,Pieris AG, a bio-pharmaceutical company ... human protein therapeutics, announced today,that its ... targeting potential. , Commenting on this ... and Preclinical Development of Pieris said: ...
... NJ (June 21, 2007) Nymox Pharmaceutical,Corporation (NASDAQ: ... Company’s recently completed studies of NX-1207 for,benign ... a series of,upcoming U.S. urology meetings, beginning ... Association Meeting in Colorado,Springs. These independent podium ...
Cached Medicine Technology:
(Date:10/10/2015)... ... October 10, 2015 , ... Isabel Healthcare will participate in the Cerner Health ... the release of the Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel ... that assist healthcare providers and consumers to potentially reduce the chance of error. The ...
(Date:10/10/2015)... ... October 10, 2015 , ... In the inaugural people’s choice contest, entitled ... To Work in Jacksonville, amongst medium-sized companies with 25 – 99 employees. The announcement ... with a celebratory gala on October 1st. , Many of the features of ...
(Date:10/9/2015)... California (PRWEB) , ... October 09, 2015 , ... ... Osteopathic Medicine of the Pacific Associate Dean for Graduate Medical Education J. Michael ... of the Year Award. Finley was selected for his impact on graduate medical ...
(Date:10/9/2015)... Los Angeles, CA (PRWEB) , ... October 09, 2015 , ... ... awareness for breast cancer victims, survivors, and the ongoing effort to find a cure. ... patients another outlet for helping women in need. With their Bra Collection Campaign, Beverly ...
(Date:10/9/2015)... ... October 09, 2015 , ... A new health tool that helps identify if ... online ( ) – just in time for the cold and flu season, ... However, for many in the U.S., the real start of cold/flu season is the ...
Breaking Medicine News(10 mins):
... ... medical journal Osteoporosis International found that women taking AdvaCAL® calcium had the highest bone ... 32 studies involved 3,169 postmenopausal women, 79 skeletal measures and 7 different types of ... ...
... ... Dermatologist settled in Dubai, received the very prestigious ,HIND RATTAN AWARD, this ... Rattan was presented at a ceremony in connection with the yearly International ... Heavy Industries and Public Enterprises, Government of India. Dr. Mehta was awarded ...
... ... IL based management consulting and technology firm, today announced it will merge ... Gold Certified Partner, effective January 1, 2010. Logan Consulting is ... America, Europe and Asia since 1992. Under the new structure, ...
... , ... Omnetics Connector Corporation, the leading manufacturer of miniature high-rel connectors, is utilizing their ... , ... MN (Vocus) January 29, 2010 -- Omnetics Connector Corporation, the leading manufacturer of ...
... ... Vemma Nutrition Company launches Vemma ... or other sports drinks, Vemma THIRST goes beyond hydration by ... minerals, while replenishing the body with necessary electrolytes, specialized carbohydrates ...
... , , Majority of Mississippi ... Jan. 28 The following is a statement by ... Consumer Healthcare Products Association (CHPA): , "Today, the Mississippi ... that, if it becomes law, will greatly limit how cold and ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: